-transparent.png){kind=logo}
The GOELAM group conducted 2 consecutive trials on the treatment of de novo acute myeloblastic leukemia (AML) in adults. In the GOELAM1 protocol 786 patients aged 15-65 were randomized between two induction treatments (ARA-C 200 mg/m2/day for 7 days plus either Idarubicin 8 mg/m2/day for 5 days or Rubidazone 200 mg/m2/day for 4 days). Out of 731 evaluable patients, 521 (71%) achieved complete remission (CR) without significant difference between the 2 anthracyclines. For patients aged 51-65, the CR rate was significantly higher with Idarubicin (75%) than with Rubidazone (61%) (p = 0.03). In this group of patients the post-remission therapy consisted in only one course of high dose ARA-C plus m-Amsa and the 6 year disease free survival (DFS) was 24% (intention to treat analysis). For patients aged 15-50 years, the post remission therapy was either allogeneic bone marrow transplantation (BMT) (patients up to 40 years of age with an HLA identical sibling) or a first course of intensive consolidation chemotherapy (ICC) followed by a randomization between autologous unpurged bone marrow transplantation (ABMT) and a second course of ICC. There was no significant difference in the 4 year DFS between allogeneic BMT (42%) and the other types of intensive post remission-therapy (40%). The 4 year DFS was 42% for ABMT and 38% for ICC (p = 0.46) (intention to treat analysis). However the median duration of thrombocytopenia was much longer after ABMT (109.5 days versus 18.5 days p = 0.0001). The GOELAM SA3 randomized placebo-controlled protocol tested the impact of GM-CSF given during and after induction treatment for elderly patients (55-75 years). In this study, 232 evaluable patients received induction chemotherapy (Idarubicin 8 mg/m2/day for 5 days plus ARA-C 100 mg/m2/day for 7 days) plus placebo or GM-CSF 5 micrograms/kg/day from day 1 until the end of neutropenia. The CR rate was 61.5%. The median duration of neutropenia was shorter in the GM-CSF arm (22 days versus 27 days p = 0.0001). There was no overall significant advantage for the GM-CSF arm, in terms of CR rate and survival. However for patients age 55-64 the 2 year DFS was significantly higher in the GM-CSF arm (43% vs 17% p = 0.0013).
J L Harousseau, and
B Pignon, and
F Witz, and
V Polin, and
Z Tellier, and
P Hurteloup, and
J Y Cahn
January 2004,
Annals of hematology,
J L Harousseau, and
B Pignon, and
F Witz, and
V Polin, and
Z Tellier, and
P Hurteloup, and
J Y Cahn
November 1974,
Minerva pediatrica,
J L Harousseau, and
B Pignon, and
F Witz, and
V Polin, and
Z Tellier, and
P Hurteloup, and
J Y Cahn
January 2001,
Therapie,
J L Harousseau, and
B Pignon, and
F Witz, and
V Polin, and
Z Tellier, and
P Hurteloup, and
J Y Cahn
February 1995,
The Journal of the Association of Physicians of India,
J L Harousseau, and
B Pignon, and
F Witz, and
V Polin, and
Z Tellier, and
P Hurteloup, and
J Y Cahn
March 1982,
JAMA,
J L Harousseau, and
B Pignon, and
F Witz, and
V Polin, and
Z Tellier, and
P Hurteloup, and
J Y Cahn
March 1973,
Therapeutique (La Semaine des hopitaux),
J L Harousseau, and
B Pignon, and
F Witz, and
V Polin, and
Z Tellier, and
P Hurteloup, and
J Y Cahn
June 1993,
Nouvelle revue francaise d'hematologie,
J L Harousseau, and
B Pignon, and
F Witz, and
V Polin, and
Z Tellier, and
P Hurteloup, and
J Y Cahn
January 1973,
Bibliotheca haematologica,
J L Harousseau, and
B Pignon, and
F Witz, and
V Polin, and
Z Tellier, and
P Hurteloup, and
J Y Cahn
January 1979,
Haematology and blood transfusion,
J L Harousseau, and
B Pignon, and
F Witz, and
V Polin, and
Z Tellier, and
P Hurteloup, and
J Y Cahn
September 1955,
Therapie der Gegenwart,
